Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.


Make more informed treatment decisions together. With the FreeStyle Libre 2 system, you can empower patients3 with user-friendly technology.4


Learn More

Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

The #1 continuous
glucose monitor (CGM) in the US§

Get your patients started on the FreeStyle Libre 2 system today with just
two sensors and an app*†‖, now available on iPhone®


  • Outstanding accuracy in the low-glucose range5 when it matters the most
  • No fingersticks required even when glucose is low, falling, or rapidly changing


  • Excellent, reliable alarm performance in the low-glucose range5
  • The first and only 14 day glucose monitoring system with alarms#5


  • The new FreeStyle Libre 2 app* lets your patient scan their sensor using their iPhone instead of the reader†‖
  • More affordable CGM at one-third the cost of other CGMs**6
  • Easy to prescribe†† with no prior authorizations required
Freestyle Libre 2 System

FreeStyle Libre 2 system Is Indicated For Patients With Diabetes Age 4 And Older

Parents and caregivers can rely on the FreeStyle Libre 2 system to make treatment decisions without confirmatory fingersticks even when glucose is low or falling5. Your patients can use the FreeStyle Libre 2 app* to monitor their glucose and share alarms# with their caregiver†,‡‡,§§

Easy to prescribe††

Prescriptions can be filled without paperwork hassles or prior authorization at participating pharmacies. Prescribe just two sensors and the free FreeStyle Libre 2 app* to your patients today§‖

Improved Diabetes Outcomes

Both real-world evidence and clinical trial results highlight the benefits of FreeStyle Libre portfolio‡,1-2,7-11

* The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.

† Medicare coverage is available for the FreeStyle Libre 2 system if a smartphone with the FreeStyle Libre 2 app is used in conjunction with the FreeStyle Libre 2 reader to review glucose data. Medicare coverage is not available if a patient never uses the FreeStyle Libre 2 reader, and patients must meet other applicable coverage criteria. See Local Coverage Determination: Glucose Monitors (L33822) and Local Coverage Article: Glucose Monitors (A52464), Jan 2020.

As a courtesy to its customers, Abbott provides the most up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.

‡ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.

§ Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.

‖ The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

¶ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

# Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device. You must have Critical Alerts enabled to receive alarms and alerts on your smartphone.

** Based on a comparison of list prices of FreeStyle Libre 2 system versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

†† No paperwork hassles or prior authorization needed at participating pharmacies. This applies to commercially insured patients. This does not apply to beneficiaries of Medicare, Medicaid, or other federal or state healthcare programs. Participating pharmacies are subject to change without notice.

‡‡ Glucose alarms will transfer to the LibreLinkUp app users when users are connected and alarms are enabled on the FreeStyle Libre 2 app.

§§ The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.

References: 1. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (February 2017): 55-73. 2. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study." Pediatr Diabetes 19, no. 7 (November 2018): 1294-1301. 3. Schumacher, Christie et al. Use of Continuous Glucose Monitoring to Improve Glycemic Management: A Clinician's Guide. Journal of America College of Clinical Pharmacy: JACCP. doi: 10.1002/jac5.1295. 4. Rodbard, David. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. Diabetes Technol Ther. 2016 Feb;18 Suppl 2(Suppl 2):S3-S13. doi: 10.1089/dia.2015.0417. PMID: 26784127; PMCID: PMC4717493. 5. Freestyle Libre 2 User's Manual. 6. Data on file. Abbott Diabetes Care. 7. Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 10057, no. 388 (September 2016): 2254-2263. 8. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (January 2020): 83-95. 9. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (January 2020): 279-291. 10. Miller, Eden, et al. "85-LB: Freestyle Libre System Use Associated with Reduction in Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes without Bolus Insulin." Diabetes 69, supp. 1 (June 2020). 11. Hirsch, Irl B. et. al. "Utilization of Continuous Glucose Monitors is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events Regardless of Prior Blood Test Strip Usage." Diabetes 69, supp. 1 (June 2020).

ADC-12852 v10.0 8/21